论文部分内容阅读
目的:观察七味通痹口服液联合尼美舒利治疗类风湿性关节炎的疗效及安全性。方法:将50例患者随机分成2组。对照组口服尼美舒利胶囊治疗,治疗组给予尼美舒利胶囊联合七味通痹口服液治疗。治疗前后分别测定血沉(ESR)、类风湿因子(RF)、C反应蛋白(CRP),并观察关节疼痛度、晨僵时间等变化。结果:治疗后2组关节疼痛度、晨僵时间、肿胀关节数、关节压痛度等6项评分均较治疗前改善,差异均有非常显著性意义(P<0.01)。治疗后,治疗组的关节疼痛度、关节压痛度2项评分均较对照组下降,差异均有显著性意义(P<0.05),提示改善关节疼痛度、关节压痛度,治疗组优于对照组。治疗后2组ESR均较治疗前明显降低,差异有显著性或非常显著性意义(P<0.05,P<0.01)。结论:七味通痹口服液联合尼美舒利治疗类风湿性关节炎,疗效确切,不良反应少。
Objective: To observe the efficacy and safety of Qiwei Tongbi oral solution combined with nimesulide in the treatment of rheumatoid arthritis. Methods: 50 patients were randomly divided into two groups. The control group was treated with nimesulide capsules. The treatment group was treated with nimesulide capsules and Qiwei Tongbi oral solution. ESR, RF and C-reactive protein (CRP) were measured before and after treatment. Changes of joint pain and morning stiffness were observed. Results: The scores of joint pain, morning stiffness, number of swollen joints and joint tenderness in the two groups after treatment were significantly improved compared with those before treatment (P <0.01). After treatment, the joint pain and joint tenderness of the treatment group were significantly lower than those of the control group (P <0.05), which suggested that the joint pain and joint tenderness were improved, and the treatment group was better than the control group . The ESR of the two groups after treatment was significantly lower than before treatment, the difference was significant or very significant (P <0.05, P <0.01). Conclusion: Qiweitongbi oral liquid combined with nimesulide treatment of rheumatoid arthritis, curative effect is exact, less adverse reactions.